SynthesisEuropean journal of medical research2023

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.

Ruijian Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.